Last reviewed · How we verify
Mass treatment with oral azithromycin to an entire community
Mass treatment with oral azithromycin to an entire community is a Small molecule drug developed by University of California, San Francisco. It is currently FDA-approved.
At a glance
| Generic name | Mass treatment with oral azithromycin to an entire community |
|---|---|
| Sponsor | University of California, San Francisco |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mass treatment with oral azithromycin to an entire community CI brief — competitive landscape report
- Mass treatment with oral azithromycin to an entire community updates RSS · CI watch RSS
- University of California, San Francisco portfolio CI
Frequently asked questions about Mass treatment with oral azithromycin to an entire community
What is Mass treatment with oral azithromycin to an entire community?
Mass treatment with oral azithromycin to an entire community is a Small molecule drug developed by University of California, San Francisco.
Who makes Mass treatment with oral azithromycin to an entire community?
Mass treatment with oral azithromycin to an entire community is developed and marketed by University of California, San Francisco (see full University of California, San Francisco pipeline at /company/university-of-california-san-francisco).
What development phase is Mass treatment with oral azithromycin to an entire community in?
Mass treatment with oral azithromycin to an entire community is FDA-approved (marketed).